Michel Bazinet

6100 Royalmount Ave
Montreal, QC H4P2R2, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.

Journal: Journal of hepatology

Published: April 11, 2025

HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure.

HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure.

Journal: Antiviral research

Published: October 28, 2024

Rapid monophasic HBsAg decline during nucleic-acid polymer-based therapy predicts functional cure.

Rapid monophasic HBsAg decline during nucleic-acid polymer-based therapy predicts functional cure.

Journal: Hepatology communications

Published: March 23, 2023

HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.

HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.

Journal: Hepatology communications

Published: December 16, 2021

Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.

Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.

Journal: Hepatology communications

Published: January 08, 2021

Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy.

Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy.

Journal: Journal of viral hepatitis

Published: January 08, 2021

Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.

Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.

Journal: Hepatology communications

Published: September 04, 2020

Data driven optimization of sexual assault case processing.

Data driven optimization of sexual assault case processing.

Journal: Forensic science international. Synergy

Published: May 14, 2020

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg.

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg.

Journal: Scientific reports

Published: February 04, 2020

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.

Journal: Gastroenterology

Published: August 01, 2019

Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg-positive chronic HBV infection.

Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg-positive chronic HBV infection.

Journal: Journal of viral hepatitis

Published: February 07, 2019

Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.

Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.

Journal: Journal of viral hepatitis

Published: June 26, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026